Dr. Lal PathLabs Ltd's Q3FY19 consolidated net profit rises 28.06% yoy to Rs46.10cr : Beats Estimates
The company’s consolidated revenue stood at Rs292.50cr, up 11.34% yoy but down 7.87% qoq.
Feb 08, 2019 03:02 IST India Infoline Research Team
Dr. Lal PathLabs Ltd Q3FY19
Consolidated Results Q3FY19: (Rs. in cr)
| Q3FY19 | YoY (%) | |
|---|---|---|
| Revenue | 292.50 | 11.3 |
| EBITDA | 65.60 | 15.9 |
| EBITDA Margin (%) | 22.4 | 88 |
| Net Profit (adjusted) | 46.10 | 28.1 |
----------------------------------------------------------------------------------------------------------------------------------------------------------------
Dr Lal Pathlabs’ revenue in Q3FY19 grew by 11.3% yoy to Rs292.5cr. EBITDA in Q3FY19 grew by 15.9% yoy to Rs65.6cr vs. Rs56.6cr in Q3FY18. EBITDA margins in Q3FY19 stood at 22.4% vs. 27.3% in Q2FY19 and 21.5% in Q3FY18. PAT in Q3FY19 grew by 28.1% yoy to Rs46.1cr vs. Rs36cr in Q3FY18.
Other Highlights
- COGS grew by 14.6% yoy to Rs65.3cr in Q3FY19. COGS as % of sales stood at 22.3% in Q3FY19 vs. 21.3% in Q2FY19 and 21.7% in Q3FY18.
- Employee cost grew by 13.1% yoy, while other expenses rose by 6.3% yoy in Q3FY18.
- Depreciation in Q3FY19 stood at Rs9.6cr in Q3FY19 vs. Rs8cr in Q3FY18.
Technical View:
Dr Lal Pathlabs Ltd is currently trading at Rs. 1,077.90, down by 11.9 points or 1.09% from its previous closing of Rs. 1,089.80 on the BSE.
The scrip opened at Rs. 1,089 and has touched a high and low of Rs. 1,111 and Rs. 1,065 respectively. So far 1,63,518 (NSE+BSE) shares were traded on the counter. The stock is currently trading below its 50 DMA.
